Remission of TP53 -Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33)
Year: 2025
Type: article
Source: JCO Precision Oncology
DOI: 10.1200/po-25-00556
Authors: Guenther Koehne, Muhammad U. Mushtaq, Lori S. Muffly, Manuel Menes, Jacques Azzi, Lea Bernard, Brenda Cooper, Vanessa Kennedy, Divya Koura, Joseph Maakaron, John Magenau, Brian McClune, Sagar S. Patel, Joseph C. Rimando, Nirali N. Shah, Hyung C. Suh, Roni Tamari, Sanjana Thosar, Giacomo Canesin, Sharon L. Hyzy, Melissa M. Lee-Sundlov, Darren A. Stanizzi, Diana Hummel, Michelle I. Lin, Glen D. Raffel, Jennifer S. Whangbo, John F. DiPersio
Institutions: Baptist Hospital of Miami, Baptist Health South Florida, University of Kansas, The University of Kansas Cancer Center, Stanford University, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Hôpital Maisonneuve-Rosemont, University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, University of California San Diego, Moores Cancer Center, University of Minnesota, University of Michigan, U-M Rogel Cancer Center, University of Utah, Huntsman Cancer Institute, Winship Cancer Institute, National Cancer Institute, Hackensack University Medical Center, Hackensack Meridian School of Medicine, Memorial Sloan Kettering Cancer Center, Washington University in St. Louis
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4415484381